Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. - Wikidata - awgldk - TriplyDB

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

http://www.wikidata.org/entity/Q37628545

about

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

P2860

Q40056586-12D6E37B-34C8-479C-9ADC-DF73A737F3BD

P2860

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.

http://www.wikidata.org/entity/Q37628545

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@en

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@nl

type

label

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@en

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@nl

prefLabel

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@en

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@nl

P1433

Q37628545-F117D58E-88BB-4AA8-B855-1C49BDDBA3D0

P1476

Q37628545-FAD86515-7B56-49A9-AC2A-C88474992249

P2093

Q37628545-09B71A95-F594-4EC5-B5E3-3B300EC6047A

Q37628545-25492FAC-7560-45EC-B055-EBBEA62F2EC5

Q37628545-2FB92A2D-B089-4B47-9ED8-0DC7E2BF3799

Q37628545-787E7CD6-4C41-414D-8779-00E082E51EAF

Q37628545-8877DA0B-7680-4103-B5B1-8E1BD34ED35D

Q37628545-92ED8DAA-7DB2-42DD-A767-A57C35965F79

Q37628545-A866B617-D570-4E4F-BFCD-BA85B8895841

Q37628545-D516CF33-F162-46CA-96D3-5D69AFB0DFBC

Q37628545-D8A7F06C-2240-4811-A89A-207ADA0AA9FB

Q37628545-FB823BF1-860C-488E-9396-9966864666C5

P2860

Q37628545-05614FD6-E7C8-4480-AF1A-9B27FB99DA3E

Q37628545-0E9C3E97-472D-494D-AC40-6EFB7D63215E

Q37628545-0FE7D682-7987-4904-AB03-B082AEBC6150

Q37628545-4491A42C-86B0-4313-8699-1AD46401DAD1

Q37628545-4C80AFA1-C30E-4004-A204-B8354FF8D796

Q37628545-51481240-425A-4BB3-ADF0-7A9E89BA0DC8

Q37628545-8B927890-3782-46CC-8720-6CDAE49E6DA8

Q37628545-9886F20B-6A7D-469B-A189-E8208F73523A

Q37628545-A6AA062B-9B08-41D0-86AE-CB8BCB88EFEA

Q37628545-BD25A470-8723-4DB8-8663-6422DC94FA4A

P304

Q37628545-6D0A95F5-B289-4CDA-BB2B-935837EEF127

P31

Q37628545-97CB7ECE-4DA6-4FEF-A1A8-7CCFF235518B

P356

Q37628545-D5F3D9F4-E709-4406-B0EF-BB421A2A1893

P433

Q37628545-4A7CA075-779E-4ED9-A3DE-7EE004D51F84

P478

Q37628545-14126893-10B7-439C-ABA6-626C68EC02F1

P577

Q37628545-5CD87E68-E477-4ADA-AAF7-FEFF65E8F9CC

P698

Q37628545-3D4BB51E-D96A-4BDD-BE80-0552154D9676

P921

Q37628545-24A2DB04-5F38-432C-B519-6193AC1B7BF7

P932

Q37628545-6D48607D-AB37-457B-8974-50E79FEA0E16

P356

P1433

World journal of hepatology

P1476

Phase 3 trial of first generat ...... odeficiency virus coinfection.

@en

P2093

Adeel A Butt

http://www.w3.org/2001/XMLSchema#string

Beverly Alston-Smith

http://www.w3.org/2001/XMLSchema#string

Jennifer J Kiser

http://www.w3.org/2001/XMLSchema#string

Kenneth E Sherman

http://www.w3.org/2001/XMLSchema#string

Kristen Marks

http://www.w3.org/2001/XMLSchema#string

Minhee Kang

http://www.w3.org/2001/XMLSchema#string

Richard Sterling

http://www.w3.org/2001/XMLSchema#string

The Actg Birth Study Team

http://www.w3.org/2001/XMLSchema#string

Triin Umbleja

http://www.w3.org/2001/XMLSchema#string

Wayne Greaves

http://www.w3.org/2001/XMLSchema#string

P2860

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Epidemiology of viral hepatitis and HIV co-infection.

Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients.

High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

P304

217-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V9.I4.217

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28217259

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5295161

http://www.w3.org/2001/XMLSchema#string